Abstract
Biotinidase (BTD) enzyme deficiency is a congenital metabolic disorder with autosomal recessive inheritance. Main symptoms in its deficiency are nervous system and skin manifestations. A 15-month-old patient who was diagnosed with Li-Campeau syndrome, was also diagnosed with BTD deficiency and his clinic rapidly improved with biotin treatment. With the awareness of different clinical presentations of BTD deficiency, patients presenting with clinical symptoms raising the suspicion of this disorder must be evaluated for enzyme activity and genetic analysis must be planned. It is of great importance to keep in mind the possibility of this rare but treatable neurometabolic disorder, even in countries with neonatal screening programme and include it in differential diagnoses in order to prevent irreversible symptoms.
Reference11 articles.
1. León-Del-Río A. Biotin in metabolism, gene expression, and human disease. J Inherit Metab Dis. 2019;42:647-654. [CrossRef]
2. Wolf B. Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have". Genet Med. 2012;14:565-575. [CrossRef]
3. Semeraro D, Verrocchio S, Di Dalmazi G, et al. High Incidence of Partial Biotinidase Deficiency in the First 3 Years of a Regional Newborn Screening Program in Italy. Int J Environ Res Public Health. 2022;19:8141. [CrossRef]
4. Canda E, Kalkan Uçar S, Çoker M. Biotinidase Deficiency: Prevalence, Impact and Management Strategies. Pediatric Health Med Ther. 2020;11:127-133. [CrossRef]
5. Oz O, Karaca M, Atas N, et al. BTD Gene Mutations in Biotinidase Deficiency: Genotype-Phenotype Correlation. J Coll Physicians Surg Pak. 2021;30:780-785. [CrossRef]